Evidence map›Paper›PMID 42533861›Full record

ArticleBJU international2026

Oncologic outcomes of radical radiotherapy in frail patients with upper tract urothelial carcinoma.

Willy Po-Yuan Chen, Wing-Keen Yap, Hao-Lun Luo, Yao-Yu Wu, Miao-Fen Chen, Shih-Ming Huang, Din-Li Tsan, Po-Hung Lin, Kai-Jie Yu, Yu-Hsiang Lin and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Willy Po-Yuan ChenDepartment of Radiation Oncology, Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.ORCID 0009-0004-9814-6872
Wing-Keen YapDepartment of Radiation Oncology, Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Hao-Lun LuoSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Yao-Yu WuDepartment of Radiation Oncology, Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Miao-Fen ChenDepartment of Radiation Oncology, Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Shih-Ming HuangDepartment of Radiation Oncology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Din-Li TsanDepartment of Radiation Oncology, Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Po-Hung LinSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0001-8245-4302
Kai-Jie YuSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Yu-Hsiang LinSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0001-9923-5747
I-Hung ShaoSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Hung-Cheng KanSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Po-Jung SuSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Wen-Kuan HuangSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Po-Jui ChenDepartment of Radiation Oncology, Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Po-Ying PengDepartment of Radiation Oncology, Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate oncologic outcomes of high-dose radical radiotherapy (RT) in medically frail patients with upper tract urothelial carcinoma (UTUC). MATERIALS AND

methodsWe retrospectively reviewed 63 patients with UTUC who received definitive RT at four major academic hospitals (2014-2021) with significant comorbidities (age-adjusted Charlson Comorbidity Index ≥3). Patients were stratified into high- and low-dose groups using a biologically effective dose (BED

resultsThe median follow-up was 76 months. The pelvic ureter was the most frequently involved site (57%), followed by the renal pelvis (33%) and the abdominal ureter (21%). In the IPTW-adjusted cohort, the disease control rate was significantly higher with high-dose RT (98% vs 62%, P < 0.001). High-dose RT significantly improved IPTW-adjusted locoregional control (3-year LRC: 51% vs 29%, P = 0.041), freedom from distant metastasis (3-year FFDM: 75% vs 39%, P = 0.001), freedom from progression (3-year FFP: 43% vs 25%, P = 0.013), and overall survival (3-year OS: 46% vs 11%, P < 0.001). Multivariate analysis identified higher RT dose as an independent prognosticator of improved FFP (adjusted hazard ratio [aHR] 0.96, P = 0.018) and OS (aHR 0.93, P < 0.001). Furthermore, pre-RT gross haematuria (aHR 2.63, P = 0.002) and age-adjusted Charlson Comorbidity Index >5 (aHR 2.85, P = 0.007) were associated with worse OS.

conclusionA clear dose-response relationship was observed in UTUC treated with definitive RT. High-dose RT was associated with significantly improved survival and represents a safe alternative for medically frail patients.

Indexed as

Carcinoma, Transitional CellKidney NeoplasmsUreteral NeoplasmsAgedAged, 80 and overFemaleFrail ElderlyHumansMaleRadiotherapy DosageRetrospective StudiesTreatment Outcomefrail elderlyproton beam radiation therapyradiotherapytransitional cell carcinomaureteral neoplasms

Identifiers

PMID42533861
PMCPMC13550793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.